BioInvent International AB (BINV) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of BioInvent International AB stock?

The P/E ratio of {name} is N/A.

Compare

2 Followers

Earnings Data

Report Date

Apr 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

―

Last Year’s EPS

-1.77

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 26, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.

Company Guidance

The management outlined a dense near‑term catalyst calendar and clear go/no‑go signals: clinical readouts are expected mid‑2026 (first Phase IIa BI‑1808+pembro in CTCL; additional BI‑1206 triplet NHL data) and in 2H‑2026 (further BI‑1808+pembro solid‑tumor data and first readout from BI‑1206+pembro in first‑line NSCLC and uveal melanoma), with concrete 2027 inflection points including completion of BI‑1808 monotherapy dose optimization in 1H‑2027 and potential pivotal starts (BI‑1808 pivotal in 2H‑2027; BI‑1206 NHL pivotal potentially 1H‑2027; BI‑1206 Phase IIb in NSCLC possibly 2H‑2027). Key clinical metrics already reported: BI‑1808 ovarian combo ORR 24% and disease control rate 57% (21 ovarian patients available), BI‑1808 CTCL monotherapy 46% ORR and 92% disease control in 13 evaluable CTCL patients (including a CR >1 year), BI‑1206 triplet in NHL ~80% ORR and 100% disease control (activity across follicular, marginal zone and mantle cell; current cohort ~30 patients), and a target benchmark of ~60% ORR for BI‑1206 in first‑line NSCLC to consider advancement. Financially, Q4‑2025 net sales were SEK 3m (vs SEK 21.4m a year earlier), full‑year net sales SEK 226m (vs SEK 45m), Q4 operating costs SEK 132m (Q4‑2024 SEK 147m), full‑year operating costs SEK 578m (2024 SEK 516m), Q4 result −SEK 125.8m and full‑year result −SEK 332.9m, with liquid funds/current investments of SEK 593m and the company assessed as financed for the coming 12 months.

Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)

Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.

Robust BI-1808 single-agent activity in T‑cell lymphoma (CTCL)

Monotherapy data in CTCL: 46% ORR and 92% DCR in 13 evaluable CTCL patients, with durable responses (including a complete response in Sézary Syndrome lasting >1 year); EMA orphan drug designation granted for BI-1808 in CTCL.

BI-1206 triplet shows high activity in non-Hodgkin lymphoma

Triplet (BI-1206 + rituximab + acalabrutinib) across follicular, marginal zone and mantle cell lymphoma: maintained ~80% ORR and 100% disease control rate; incremental 4 partial responses and 1 additional stable disease vs prior dataset, demonstrating activity across subtypes and encouraging duration.

Promising solid tumor signals for BI-1206 and advancement to first-line studies

Dose-escalation signals in PD-1/PD-L1 refractory solid tumors (complete and partial responses) supported opening a Phase IIa first-line program with pembrolizumab in non‑small cell lung cancer (NSCLC) and uveal melanoma; first readout expected H2 2026.

Strategic collaborations with large pharma

Supply and collaboration agreements in place with Merck (pembrolizumab combinations) and AstraZeneca (acalabrutinib supply for NHL), enabling first-line combination studies and providing strong external validation for programs.

Dense forward-looking clinical milestone timetable

Multiple near-term catalysts: additional BI-1808 combo and monotherapy Phase IIa readouts mid/late 2026; BI-1206 NHL update mid-2026; first-line BI-1206+KEYTRUDA readout H2 2026; potential pivotal starts in 2027 contingent on data.

Board strengthening and scientific depth

Two experienced board nominees (Kate Hermans, Scott Zinober) and publication of mechanistic/preclinical work that deepens scientific credibility and supports partnering discussions.

Improved full-year net sales (driven by one-time items) and short-term liquidity

Net sales for Jan–Dec 2025 were SEK 226 million vs SEK 45 million in 2024 (increase of SEK 181 million, ~+402%), driven mainly by a SEK 20 million payment (XOMA Royalty transaction) and a SEK 1 million milestone; liquid funds and current investments SEK 593 million at 31 Dec 2025 and company assessed as financed for the coming 12 months.

BioInvent International AB (SE:BINV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:BINV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 29, 2026	2026 (Q1)	- / -	-1.772	―	―	―
Feb 26, 2026	2025 (Q4)	- / -	-1.776	―	―
Oct 29, 2025	2025 (Q3)	- / -1.96	-1.478	-32.88% (-0.49)	―
Aug 26, 2025	2025 (Q2)	- / 0.59	-2.087	128.27% (+2.68)	―	―
Apr 29, 2025	2025 (Q1)	- / -1.77	-1.184	-49.66% (-0.59)	―	―
Feb 27, 2025	2024 (Q4)	- / -1.78	-1.476	-20.33% (-0.30)	―
Oct 31, 2024	2024 (Q3)	- / -1.48	-1.08	-36.85% (-0.40)	―
Aug 29, 2024	2024 (Q2)	- / -2.09	-1.343	-55.40% (-0.74)	―	―
Apr 24, 2024	2024 (Q1)	- / -1.18	-1.12	-5.71% (-0.06)	―	―
Feb 22, 2024	2023 (Q4)	- / -1.48	-1.206	-22.39% (-0.27)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:BINV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 26, 2026	kr26.30	kr23.30	-11.41%
Oct 29, 2025	kr27.30	kr31.10	+13.92%
Aug 26, 2025	kr36.15	kr33.25	-8.02%
Apr 29, 2025	kr29.30	kr30.90	+5.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioInvent International AB (SE:BINV) report earnings?

BioInvent International AB (SE:BINV) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).

What is BioInvent International AB (SE:BINV) earnings time?

BioInvent International AB (SE:BINV) earnings time is at Apr 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BioInvent International AB stock?

The P/E ratio of BioInvent International AB is N/A.

What is SE:BINV EPS forecast?

Currently, no data Available